{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:05:08Z","timestamp":1791014708087,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1038\/ncprheum0620","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T13:04:24Z","timestamp":1190984664000},"page":"561-569","source":"Crossref","is-referenced-by-count":74,"title":["B-cell lymphoproliferation in chronic inflammatory rheumatic diseases"],"prefix":"10.1038","volume":"3","author":[{"given":"Arne","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0620_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1056\/NEJM200007133430207","volume":"343","author":"PJ Delves","year":"2000","unstructured":"Delves PJ and Roitt IM (2000) The immune system. Second of two parts. N Engl J Med 343:108\u2013117","journal-title":"N Engl J Med"},{"key":"BFncprheum0620_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch A et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741\u2013750","journal-title":"Nat Rev Immunol"},{"key":"BFncprheum0620_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2005.06.011","volume":"5","author":"P Youinou","year":"2006","unstructured":"Youinou P et al. (2006) B lymphocytes in the front line of autoimmunity. Autoimmun Rev 5: 215\u2013221","journal-title":"Autoimmun Rev"},{"key":"BFncprheum0620_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ni0901-764","volume":"2","author":"PE Lipsky","year":"2001","unstructured":"Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2: 764\u2013766","journal-title":"Nat Immunol"},{"key":"BFncprheum0620_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/ar603","volume":"4","author":"T D\u00f6rner","year":"2002","unstructured":"D\u00f6rner T and Lipsky PE (2002) Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sj\u00f6gren's syndrome. Arthritis Res 4: 360\u2013371","journal-title":"Arthritis Res"},{"key":"BFncprheum0620_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI (2005) Sj\u00f6gren's syndrome. Lancet 366: 321\u2013331","journal-title":"Lancet"},{"issue":"Suppl 3","key":"BFncprheum0620_CR7","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/ar1737","volume":"7","author":"CM Weyand","year":"2005","unstructured":"Weyand CM et al. (2005) B cells in rheumatoid synovitis. Arthritis Res Ther 7 (Suppl 3): S9\u2013S12","journal-title":"Arthritis Res Ther"},{"key":"BFncprheum0620_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/01.bor.0000218950.27483.80","volume":"18","author":"KP Machold","year":"2006","unstructured":"Machold KP et al. (2006) Early rheumatoid arthritis. Curr Opin Rheumatol 18: 282\u2013288","journal-title":"Curr Opin Rheumatol"},{"key":"BFncprheum0620_CR9","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"E Zintsaras","year":"2005","unstructured":"Zintsaras E et al. (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337\u20132344","journal-title":"Arch Intern Med"},{"key":"BFncprheum0620_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","volume":"5","author":"S De Vita","year":"2006","unstructured":"De Vita S and Quartuccio L (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5: 443\u2013448","journal-title":"Autoimmun Rev"},{"key":"BFncprheum0620_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT et al. (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5: 341\u2013353","journal-title":"Lancet Oncol"},{"key":"BFncprheum0620_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ni0901-793","volume":"2","author":"IR Mackay","year":"2001","unstructured":"Mackay IR and Rose NR (2001) Autoimmunity and lymphoma: tribulations of B cells. Nat Immunol 2: 793\u2013795","journal-title":"Nat Immunol"},{"key":"BFncprheum0620_CR13","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood.V100.9.3419","volume":"100","author":"S Ruzickova","year":"2002","unstructured":"Ruzickova S et al. (2002) Chronic lymphocytic leukemia preceded by cold-agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H) 4-34 expressing single leukemic B cells. Blood 100: 3419\u20133422 [Erratum in: Blood 2003; 101: 1676]","journal-title":"Blood"},{"key":"BFncprheum0620_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/ard.2005.035311","volume":"64","author":"P Geborek","year":"2005","unstructured":"Geborek P et al. (2005) Tumor necrosis factor blockers do not increase overall risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64: 657\u2013658","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0620_CR15","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.22056","volume":"54","author":"S Setoguchi","year":"2006","unstructured":"Setoguchi S et al. (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54: 2757\u20132764","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR16","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275\u20132285","journal-title":"JAMA"},{"key":"BFncprheum0620_CR17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1073\/pnas.98.3.1166","volume":"98","author":"S Weller","year":"2001","unstructured":"Weller S et al. (2001) CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA 98: 1166\u20131170","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0620_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","volume":"42","author":"M Voulgarelis","year":"1999","unstructured":"Voulgarelis M et al. (1999) Malignant lymphoma in primary Sj\u00f6gren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sj\u00f6gren's syndrome. Arthritis Rheum 42: 1765\u20131772","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR19","first-page":"438","volume":"24","author":"P Manganelli","year":"2006","unstructured":"Manganelli P et al. (2006) Hematologic manifestations of primary Sj\u00f6gren's syndrome. Clin Exp Rheumatol 24: 438\u2013448","journal-title":"Clin Exp Rheumatol"},{"key":"BFncprheum0620_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"E Theander","year":"2006","unstructured":"Theander E et al. (2006) Lymphoma and other malignancies in primary Sj\u00f6gren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65: 796\u2013803","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0620_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jnci\/djj004","volume":"98","author":"KE Smedby","year":"2006","unstructured":"Smedby KE et al. (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51\u201360","journal-title":"J Natl Cancer Inst"},{"key":"BFncprheum0620_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S Monti","year":"2005","unstructured":"Monti S et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851\u20131861","journal-title":"Blood"},{"key":"BFncprheum0620_CR23","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1002\/art.22277","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E et al. (2006) Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 54: 3774\u20133781","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/jnci\/djj361","volume":"98","author":"O Landgren","year":"2006","unstructured":"Landgren O et al. (2006) Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 98: 1321\u20131330","journal-title":"J Natl Cancer Inst"},{"key":"BFncprheum0620_CR25","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","volume":"23","author":"D Re","year":"2005","unstructured":"Re D et al. (2005) Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 23: 6379\u20136386","journal-title":"J Clin Oncol"},{"key":"BFncprheum0620_CR26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","volume":"101","author":"M S\u00e1nchez-Beato","year":"2003","unstructured":"S\u00e1nchez-Beato M et al. (2003) Cell cycle deregulation in B cell lymphomas. Blood 101: 1220\u20131235","journal-title":"Blood"},{"key":"BFncprheum0620_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrc1409","volume":"4","author":"PG Isaacson","year":"2004","unstructured":"Isaacson PG and Du MQ (2004) MALT lymphoma: from morphology to molecules. Nat Rev Cancer 4: 644\u2013653","journal-title":"Nat Rev Cancer"},{"key":"BFncprheum0620_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1365-2141.2005.05613.x","volume":"130","author":"A Carbone","year":"2005","unstructured":"Carbone A and Gloghini A (2005) AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 130: 662\u2013670","journal-title":"Br J Haematol"},{"key":"BFncprheum0620_CR29","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J et al. (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cell are associated with improved survival in follicular lymphoma. Blood 108: 2957\u20132964","journal-title":"Blood"},{"key":"BFncprheum0620_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas AM et al. (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25: 390\u2013398","journal-title":"J Clin Oncol"},{"key":"BFncprheum0620_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2141.2007.06593.x","volume":"137","author":"S Hasselblom","year":"2007","unstructured":"Hasselblom S et al. (2007) The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 137: 364\u2013373","journal-title":"Br J Haematol"},{"key":"BFncprheum0620_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/modpathol.3880521","volume":"15","author":"ES Jaffe","year":"2002","unstructured":"Jaffe ES (2002) Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Mod Pathol 15: 255\u2013263","journal-title":"Mod Pathol"},{"key":"BFncprheum0620_CR33","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/art.11311","volume":"48","author":"S Salomonsson","year":"2003","unstructured":"Salomonsson S et al. (2003) Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren's syndrome. Arthritis Rheum 48: 3187\u20133201","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.smim.2003.08.002","volume":"15","author":"T Cupedo","year":"2003","unstructured":"Cupedo T and Mebius RE (2003) Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 15: 243\u2013248","journal-title":"Semin Immunol"},{"key":"BFncprheum0620_CR35","first-page":"1190","volume":"10","author":"M Du","year":"1996","unstructured":"Du M et al. (1996) Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in clonal expansion. Leukemia 10: 1190\u20131197","journal-title":"Leukemia"},{"key":"BFncprheum0620_CR36","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V91.6.1864","volume":"91","author":"S Bahler","year":"1998","unstructured":"Bahler S and Swerdlow SH (1998) Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sj\u00f6gren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 91: 1864\u20131872","journal-title":"Blood"},{"key":"BFncprheum0620_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/1529-0131(200004)43:4<908::AID-ANR24>3.0.CO;2-K","volume":"43","author":"T Martin","year":"2000","unstructured":"Martin T et al. (2000) Salivary gland lymphomas in patients with Sj\u00f6gren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43: 908\u2013916","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/art.21558","volume":"54","author":"Hansen","year":"2006","unstructured":"Hansen et al. (2006) Dissemination of a Sj\u00f6gren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutational pattern of nodal Ig heavy and light chain variable-region gene rearrangements. Arthritis Rheum 54: 127\u2013137","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR39","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","volume":"104","author":"S Weller","year":"2004","unstructured":"Weller S et al. (2004) Human blood IgM \u201cmemory\u201d B cells are circulating splenic marginal zone B cells harbouring a prediversified immunoglobulin repertoire. Blood 104: 3647\u20133654","journal-title":"Blood"},{"key":"BFncprheum0620_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1084\/jem.20052033","volume":"203","author":"M Tsuiji","year":"2006","unstructured":"Tsuiji M et al. (2006) A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 203: 293\u2013400","journal-title":"J Exp Med"},{"key":"BFncprheum0620_CR41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.pharmthera.2006.06.002","volume":"112","author":"AP Sutherland","year":"2006","unstructured":"Sutherland AP et al. (2006) Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112: 774\u2013786","journal-title":"Pharmacol Ther"},{"key":"BFncprheum0620_CR42","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.4049\/jimmunol.178.5.2872","volume":"178","author":"R Ettinger","year":"2007","unstructured":"Ettinger R et al. (2007) IL21 & BAFF\/BlyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 178: 2872\u20132882","journal-title":"J Immunol"},{"key":"BFncprheum0620_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"J Groom","year":"2002","unstructured":"Groom J et al. (2002) Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren's syndrome. J Clin Invest 109: 59\u201368","journal-title":"J Clin Invest"},{"key":"BFncprheum0620_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4049\/jimmunol.172.2.812","volume":"172","author":"M Batten","year":"2004","unstructured":"Batten M et al. (2004) TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172: 812\u2013822","journal-title":"J Immunol"},{"key":"BFncprheum0620_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0049-0172(96)80019-9","volume":"25","author":"JM Anaya","year":"1996","unstructured":"Anaya JM et al. (1996) Clinicopathological factors relating malignant lymphoma with Sj\u00f6gren's syndrome. Semin Arthritis Rheum 25: 337\u2013346","journal-title":"Semin Arthritis Rheum"},{"key":"BFncprheum0620_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.autrev.2004.04.004","volume":"4","author":"M Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M et al. (2005) Hepatitis C virus, Sj\u00f6gren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 4: 8\u201315","journal-title":"Autoimmun Rev"},{"key":"BFncprheum0620_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.blre.2006.12.002","volume":"21","author":"A Tedeschi","year":"2007","unstructured":"Tedeschi A et al. (2007) Cryoglobulinemia. Blood Rev 21: 183\u2013200","journal-title":"Blood Rev"},{"key":"BFncprheum0620_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/rheumatology\/kel174","volume":"46","author":"M Fabris","year":"2007","unstructured":"Fabris M et al. (2007) B-lymphocyte stimulator (BlyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology 46: 37\u201343","journal-title":"Rheumatology"},{"key":"BFncprheum0620_CR49","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/art.1780390508","volume":"39","author":"AG Tzioufas","year":"1996","unstructured":"Tzioufas AG et al. (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj\u00f6gren's syndrome. Arthritis Rheum 39: 767\u2013772","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR50","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/art.10221","volume":"46","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis JP et al. (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome. Arthritis Rheum 46: 741\u2013747","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1006\/bcmd.2001.0446","volume":"27","author":"S De Vita","year":"2001","unstructured":"De Vita S et al. (2001) Preliminary classification of nonmalignant B cell proliferation in Sj\u00f6gren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular approach. Blood Cells Mol Dis 27: 757\u2013766","journal-title":"Blood Cells Mol Dis"},{"key":"BFncprheum0620_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/ard.2006.052159","volume":"66","author":"JE Gottenberg","year":"2007","unstructured":"Gottenberg JE et al. (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and Sj\u00f6gren's syndrome. Ann Rheum Dis 66: 23\u201327","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0620_CR53","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/art.21029","volume":"52","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S et al. (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52: 1481\u20131490","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR54","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","volume":"11","author":"M Raderer","year":"2005","unstructured":"Raderer M et al. (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 11: 3349\u20133352","journal-title":"Clin Cancer Res"},{"key":"BFncprheum0620_CR55","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J et al. (2005) Rituximab treatment in patients with Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum 52: 2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0620_CR56","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/ard.2004.030684","volume":"64","author":"J Pijpe","year":"2005","unstructured":"Pijpe J et al. (2005) Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sj\u00f6gren's syndrome and associated MALT lymphoma. Ann Rheum Dis 64: 958\u2013960","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0620_CR57","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/ard.2005.046193","volume":"65","author":"M Voulgarelis","year":"2006","unstructured":"Voulgarelis M et al. (2006) Long term remission of Sj\u00f6gren's syndrome associated aggressive B cell non Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) Ann Rheum Dis 65: 1033\u20131037","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0620_CR58","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD et al. (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study. Arthritis Res Ther 8: R129","journal-title":"Arthritis Res Ther"},{"key":"BFncprheum0620_CR59","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1586\/14737140.6.10.1341","volume":"6","author":"DM Golenberg","year":"2006","unstructured":"Golenberg DM (2006) Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 6:1341\u20131353","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0620","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:07:58Z","timestamp":1684444078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["BFncprheum0620"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0620","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}